Use of selective inhibitors of Arginase 2 and Tadalafil in combined compensation of homocysteine-induced endothelial dysfunction
DOI:
https://doi.org/10.18413/2500-235X-2015-1-4-15-20Аннотация
Use of selective inhibitors of arginase 2 in combination with tadalafil on in the course of modeling of homocysteine-induced endothelial dysfunction provided endotelio- and cardioprotective effects manifested in preventing of SED increase, adrenoreactivity, maintaining myocardial reserve and normalization of the values of biochemical markers (Total NO, expression of eNOS).
Ключевые слова:
endothelial dysfunction, selective inhibitors of arginase 2, tadalafilБиблиографические ссылки
Korokin М.V., Pokrovsky М.V., Novikov О.О., Gudyrev О.S., Gureev V.V., Denisik Т.А., Korokina L.V., Danilenko L.М., Ragulina V.А., Konovalova Ye.А., Belous А.S. A model of hyperhomocistein-induced endothelial dysfunction in rats.//Bulletin of Experimental Biology and Medicine. 2011. V. 152. № 8. P. 173-175.
Kochkarov V.I., Pokrovsky М.V., Korneev М.М., Pokrovskaya T.G., Gladchenko М.P., Artiushkova Ye.B., Metelskaya V.А., Tumanova N.G., Faitelson А.V., Dudka V.Т., Kliavs Yu.P., Zelenkova Т.I., Gudyrev О.S. Endothelium-protective effects of resveratrol and its combinations with enalapril and losartan in the course of experimental modeling of nitric oxide deficiency.//Kuban Scientific Medical Bulletin. 2006. № 9. P. 150-152.
Korokin М.V., Pashin Ye.N., Bobrakov K.Ye., Pokrovsky М.V., Ragulina V.А., Artiushkova Ye.B., Pokrovskaya T.G., Danilenko L.М., Tsybulsky I.V., Tsepelev V.Yu. Endothelium-protective, cardioprotective and coronarolytic effects of 3-oxypyridine derivatives.// Kursk Research and Practice Bulletin "Man and its health". 2009. № 4. P. 11-19.
Gumanova N.G., Artiushkova Ye.B., Metelskaya V.А., Kochkarov V.I., Pokrovskaya T.G., Danilenko L.М., Korneev М.М., Pokrovsky М.V., Pashin Ye.N. Effect of antioxidants q510 and resveratrol on the regulatory function of the endothelium in rats with simulated arterial hypertension // Bulletin of Experimental Biology and Medicine. 2007. V. 143. № 6. P. 619-622.
Korokin М.V., Nosov А.М., Pokrovsky М.V., Artiushkova Ye.B., Pokrovskaya T.G., Metelskaya V.А., Kochkarov V.I., Korokina L.V., Faitelson А.V., Gudyrev О.S., Pashin Ye.N., Dudka V.Т., Tumanova N.G. Comparative study of endothelio- and cardioprotective properties of furostanolic glycosides extracted from cell culture of Dioscorea Deltoidea plant and 17p-estradiol// Kuban Scientific Medical Bulletin. 2006. № 9. P. 137-140.
Pokrovsky М.V., Pokrovskaya T.G., Gureev V.V., Barsuk А.А., Proskuriakova Ye.V., Korokin М.V., Belous А.S., Korokina L.V., Ragulina V.А., Gudyrev О.S., Levashova О.V., Korolev А.Ye., Maltseva N.V., Polianskaya О.S., Terekhova Ye.G., Babko А.V., Novikov О.О., Zhyliakova Ye.Т., Sorokopudov V.N., Kolesnik I.М. et al. Pharmacological correction of ADMA-ЕNOS-associated targets in preeclampsia // Obstetrics and Gynecology Journal. 2011. № 2. P. 16-20.
Pokrovskiy M.V., PokrovskayaT.G., Kochkarov V.I., Korokin M.V., GureevV.V., Gudyrev O.S., Tsepeleva S.A., KonovalovaE.A., KorokinaL.V., Dudina E.N., Babko A.V., Terehova E.G Аrginase inhibitor in the pharmacological correction of endothelial dysfunction.// International Journal of Hypertension. 2011. Т. 2011. С. 515047
Pokrovsky М.V., Artiushkova Ye.B., Pokrovskaya T.G. Methods of experimental simulation of endothelial dysfunction // Allergology and Immunology Journal. 2008. V. 9. № 3. P. 327.
Artiushkova Ye.V., Pokrovsky М.V., Artiushkova Ye.B., Korokin M.V., Gudyrev O.S., Belous А.S. Endothelio- and cardioprotective effects of meldonium and trimetazidine in the model of L-NAME-induced endothelial dysfunction // Kursk Research and Practice Bulletin "Man and its health". 2010. № 3. P. 5-10.
Michell DL, Andrews KL, Chin- Dusting JP. Endothelial dysfunction in hypertension: the role of arginase. Front Biosci (Schol Ed) 2011;3:946-960.
Santhanam L, Lemmon CA, Soucy KG, Gupta G, White AR, Ny han D, et al. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006;99:951-960.
Romero MJ, Platt DH, Tawfik HE,Labazi M, El-Remessy AB, Bartoli M, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102:95-102.
Christianson DW, Nyhan D, Berkowitz DE. Argin ase and vascular aging. J Appl Physiol2008;105:1632-1642.
Prieto CP, Krause BJ, Quezada C, San artin R, Sobrevia L, Casanello P.Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium. Placenta 2011;32:932-940.
Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M, et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation2012;126:2943-2950
Quitter F, Figulla HR, Ferrari M, Pernow J, Jung C. Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. ClinHemorheolMicrocirc. Advance Access published October 17, 2012, doi: 10.3233/CH-2012-1617.
Holowatz LA, Kenney WL. Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans. J Physiol 2007;581:863-872
Schade D, Kotthaus J, Clement B. Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease. PharmacolTherap 2010;126:279-300.
Bagnost T, Ma L, da Silva RF, Rezakhaniha R, Houdayer C, Stergiopulos N, et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res2010;87:569-577.
Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008;102:923-932.
Русский
English
